ESOC 2024 | Colchicine to reduce cardiovascular events after stroke

Aristeidis Katsanos, MD, from McMaster University, Hamilton, Ontario, Canada, expresses his excitement at the results of the CONVINCE trial (NCT02898610), a large, Phase III, international clinical trial testing colchicine for secondary stroke prevention. The trial provided promising results, in which patients taking the medication had a lower risk of a major cardiovascular event or recurrent stroke. C-reactive protein levels were also lower in these patients, implying the drug successfully reduced inflammation. Studies are also looking at colchicine after hemorrhagic stroke. Having completed a pilot phase study, it is hoped that moving to a Phase III international trial will reveal more about the abilities of colchicine to reduce the risk of cardiovascular events if given after acute intracranial hemorrhage. This interview took place at the 10th European Stroke Organisation Conference (ESOC) 2024 in Basel, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.